• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Oragenics Inc.

    12/16/24 4:05:57 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OGEN alert in real time by email
    S-8 1 forms-8.htm

     

    As Filed with the Securities and Exchange Commission on December 16, 2024

     

    Registration No. 333-________

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    ORAGENICS, INC.

    (Exact name of registrant as specified in its charter)

     

    FLORIDA   59-3410522

    (State or other jurisdiction of

    incorporation or organization

     

    (I.R.S. Employer

    Identification No.)

     

    1990 Main Street, Suite 750

    Sarasota, FL 34236

    813-286-7900

    (Address, including zip code, and telephone number, including area code of registrant’s principal executive offices)

     

     

    2021 EQUITY INCENTIVE PLAN

    (Full Title of the Plans)

     

     

    Janet Huffman,

    Chief Financial Officer.

    1990 Main Street, Suite 750

    Sarasota, FL 34236

    813-286-7900

    (Name, Address and Telephone number of Agent for Service)

     

    Copies to:

     

     

    Mark A. Catchur, Esquire

    Julio C. Esquivel, Esquire

    Shumaker, Loop & Kendrick, LLP

    101 E. Kennedy Blvd., Suite 2800

    Tampa, Florida 33602

    (813) 229-7600

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

     

    Large Accelerated Filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
      Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    REGISTRATION OF ADDITIONAL SECURITIES

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 of Oragenics, Inc. (the “Company”) is being filed to register 2,000,000 additional shares of Company common stock authorized for issuance under the 2021 Equity Incentive Plan (the “2021 Plan”) (which is an amendment and restatement of the Company’s 2012 Equity Incentive Plan), pursuant to General Instruction E to Form S-8. The table below summarizes the Plan, as amended to date and the registration statements previously filed to cover shares authorized for issuance under the Plan.

     

    Summary Plan Table

     

    Plan History 

    Date

     

    Authorized

    Shares

      

    Post-Split

    Shares

      

    Registration

    Statement

    2021 Equity Incentive Plan  February 2022   10,000,000*   166,667   333-263821
     First Amendment to 2021 Plan  December 2023   1,000,000    1,166,667   333-276460
     Second Amendment to 2021 Plan  December 2024   2,000,000    3,166,667    

     

     

    *On January 20, 2023, the Company effected a 1 for 60 reverse stock split and the amounts reflected prior to the January 2023 reverse split have been adjusted for such reverse split. On December 14, 2023, the Company’s shareholders approved an increase in the number of authorized shares for issuance under the Plan from 166,667 shares to 1,166,667 shares or an additional 1,000,000 shares. On December 11, 2024, the Company’s shareholders approved an increase in the number of authorized shares for issuance under the Plan from 1,166,667 shares to 3,166,667 shares or an additional 2,000,000 shares. This Registration Statement registers the additional 2,000,000 shares approved by the Company’s shareholders.

     

    Pursuant to General Instruction E to Form S-8, the contents of the previously filed Registration Statement, on Form S-8 (No. 333-263821), on March 24, 2022, is incorporated herein by reference, except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the earlier registration statements are presented herein.

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The document(s) containing the information specified in Part I of Form S-8 will be sent or given to participants as specified by Securities Act Rule 428(b)(1).

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    This Registration Statement on Form S-8 incorporates by reference the following documents we previously filed with the Securities and Exchange Commission:

     

      ● Registration Statement on Form S-8 filed March 24, 2022 (File No. 333-263821) and Registration Statement on Form S-8 filed January 10, 2024 (File No. 333-276460);
         
      ● the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Commission on March 29, 2024;
         
      ● the Registrant’s Quarterly Report on Form 10-Q for the quarters ended March 31, 2024, June 30, 2024, and September 30, 2024, filed with the Commission on May 15, 2024, August 9, 2024 and November 13, 2024, respectively;
         
      ● the Registrant’s Current Reports on Form 8-K, filed with the Commission on each of January 2, 2024, January 16, 2024, January 23, 2024, February 5, 2024, February 7, 2024, February 12, 2024, February 28, 2024, February 28, 2024, March 1, 2024, March 18, 2024, April 16, 2024, April 22, 2024, May 7, 2024, May 16, 2024, May 17, 2024, May 22, 2024, May 23, 2024, June 20, 2024; June 26, 2024, July 10, 2024, July 22, 2024, August 8, 2024, August 12, 2024, August 14, 2024, August 16, 2024, August 21, 2024, September 5, 2024, September 20, 2024, October 9, 2024, October 15, 2024, October 16, 2024, October 18, 2024 and November 29, 2024.

     

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, subsequent to the effective date of this Registration Statement, prior to the filing of a post-effective amendment to this Registration Statement indicating that all securities offered hereby have been sold or deregistering all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such documents. In no event, however, will any information that the Registrant discloses under Item 2.02 or Item 7.01 (and any related exhibits) of any Current Report on Form 8-K that the Registrant may from time to time furnish to the Commission be incorporated by reference into, or otherwise become a part of, this Registration Statement. Any statement contained in any document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed to constitute a part of this Registration Statement, except as so modified or amended, to constitute a part of the Registration Statement.

     

    Item 8. Exhibits.

     

    See the Exhibit Index immediately following the signature page which is incorporated herein by reference.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Tampa, State of Florida this 16th day of December, 2024.

     

      Oragenics, Inc.
         
      By: /s/ Janet Huffman
        Janet Huffman
       

    Chief Financial Officer and

    Principal Financial Officer

     

    POWER OF ATTORNEY

     

    Each of the undersigned officers and directors of Oragenics, Inc., hereby constitutes and appoints Janet Huffman, as their true and lawful attorney-in-fact and agents, for them and in their name, place and stead, in any and all capacities, to sign their names to any and all amendments to this Registration Statement on Form S-8, including post-effective amendments and other related documents, and to cause the same to be filed with the Securities and Exchange Commission, granting unto said attorneys, full power and authority to do and perform any act and thing necessary and proper to be done in the premises, as fully to all intents and purposes as the undersigned could do if personally present, and the undersigned for himself hereby ratifies and confirms all that said attorney shall lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this S-8 Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Janet Huffman   Chief Financial Officer, Interim Principal Executive Officer and Principal   December 16, 2024
    Janet Huffman   Accounting Officer    
             
    /s/ Charles Pope   Executive Chairman of the Board and   December 16, 2024
    Charles L. Pope   Director    
             
    /s/ Frederick W. Telling   Director   December 16, 2024
    Frederick W. Telling        
             
    /s/ Robert C. Koski   Director   December 16, 2024
    Robert C. Koski        
             
    /s/ Alan W. Dunton   Director   December 16, 2024
    Alan W. Dunton        
             
    /s/ John Gandolfo   Director   December 16, 2024
    John Gandolfo        
             
    /s/ Bruce Cassidy   Director   December 16, 2024
    Bruce Cassidy        

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit

    Number

      Exhibit Description
         
    4.1   2021 Equity Incentive Plan (incorporated by reference as Exhibit 10.1 to Form 8-K filed on February 28, 2022).
         
    4.2   First Amendment to Equity Incentive Plan (incorporated by reference to Exhibit 4.2 to Form 8-K filed on December 15, 2023)
         
    4.3   Second Amendment to Equity Incentive Plan.
         
    4.4   Form of Warrant to purchase shares of Common Stock (incorporated by reference as Exhibit 4.2 to Form S-1/A filed on July 9, 2018).
         
    4.5   Warrant Agency Agreement (incorporated by reference as Exhibit 4.2 to Form 8-K filed on July 17, 2018).
         
    4.6   Warrant dated May 1, 2020 (incorporated by reference as Exhibit 4.1 to Form 8-K filed on May 4, 2020).
         
    4.7   Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to Form 8-K filed on September 5, 2024
         
    4.8  

    Form of Placement Agent Warrant. (incorporated by reference to Exhibit 4.2 to Form 8-K filed on September 5, 2024.

         
    4.9   Warrant Agency Agreement (incorporated by reference to Exhibit 4.3 to Form 8-K filed on September 5, 2024
         
    4.10   Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference as Exhibit 4.9 to Form 10-K filed on April 17, 2023).
         
    5.1   Opinion of Shumaker, Loop & Kendrick, LLP, as to the legality of the securities being registered.
         
    23.1   Consent of Independent Registered Public Accounting Firm, Cherry Bekaert, LLP.
         
    23.2   Consent of Independent Registered Public Accounting Firm, CBIZ CPAs P.C.
         
    23.3   Consent of Shumaker, Loop & Kendrick, LLP to the use of their opinion as an Exhibit to this Registration Statement is included in the opinion filed herewith as Exhibit 5.1.
         
    24.1   Power of Attorney (included with the signature page to this Registration Statement).
         
    107   Filing Fee Table.

     

     

     

    Get the next $OGEN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OGEN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OGEN
    SEC Filings

    View All

    SEC Form S-3 filed by Oragenics Inc.

    S-3 - ORAGENICS INC (0001174940) (Filer)

    1/22/26 4:11:24 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - ORAGENICS INC (0001174940) (Filer)

    1/22/26 4:05:42 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ORAGENICS INC (0001174940) (Filer)

    1/20/26 8:30:52 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care

    Management to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Treatment Sarasota, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN) ("the "Company"), a clinical-stage biotechnology company focused on developing intranasal therapeutics for neurological disorders, today announced its participation at the SCOPE Summit 2026, the 17th annual conference organized by the Cambridge Healthtech Institute. SCOPE (Summit for Clinical Ops Executives) is a clinical research conference being held February 2–5, 2026, in Orlando, Florida. "Oragenics is excited to participate in one of the premier global conferences for clinical operations and optimal t

    2/2/26 8:30:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico

    Sarasota, Fla., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN) ("the "Company") today announced that it will be presenting at the upcoming Sequire Investor Summit 2026. The fourth edition of the Sequire Investor Summit is scheduled for January 20th-22nd, 2026, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. "We appreciate the opportunity to present at the Sequire Investor Summit and discuss our novel approach to addressing the significant unmet medical need in concussion and mild traumatic brain injury," said Janet Huffman, CEO of Oragenics. "There are currently no approved drug therapies for concussion, underscoring the importance of advancing our ONP-002 clinica

    1/14/26 8:30:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics Q3 2025 Shareholder Update

    Building on Solid Ground: From Vision to Execution Restoring Compliance, Advancing Innovation, Preparing for Clinical Milestones Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today reported key operational, financial, and strategic achievements for the third quarter of 2025. These milestones reflect the Company's evolution from vision to execution as it advances toward critical clinical trial initiation in Q4 2025/Q1 2026. OPERATIONAL EXCELLENCE: FOUNDATION RESTORED NYSE American Compliance Regained On October 20, 2025, Oragenics regained full compliance with NYSE Ameri

    11/12/25 8:30:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Telling Fred sold $198 worth of shares (210 units at $0.94), decreasing direct ownership by 18% to 948 units (SEC Form 4)

    4/A - ORAGENICS INC (0001174940) (Issuer)

    1/22/26 1:04:30 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO and CFO Huffman Janet

    4 - ORAGENICS INC (0001174940) (Issuer)

    12/15/25 4:55:39 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Giordano Natasha

    4 - ORAGENICS INC (0001174940) (Issuer)

    12/15/25 4:49:15 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman Sachs initiated coverage on Oragenics with a new price target

    Goldman Sachs initiated coverage of Oragenics with a rating of Neutral and set a new price target of $52.00

    6/3/21 6:23:39 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    Financials

    Live finance-specific insights

    View All

    Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock

    TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has raised approximately $20 million from the sale of common stock through a sales agreement with A.G.P./Alliance Global Partners for an “at-the-market” facility. In addition, the Company also received approximately $1.9 million from the exercise of common stock warrants. In turn, Oragenics has given a notice for the redemption of all outstanding shares of the Company’s Series C, Non-Convertible, Preferred Stock (the “Series C Preferred Stock”) to the holder of the Series C Preferred Stock. Commenting on these developments, Alan Joslyn, President and Chief Executive Offic

    2/12/21 8:00:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    Leadership Updates

    Live Leadership Updates

    View All

    Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health

    SARASOTA, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, proudly announces that its Chief Medical Officer, Dr. James Kelly, has been appointed to the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health. The Leigh Steinberg Foundation is dedicated to advancing brain health by supporting research, raising awareness, and driving actionable solutions for those affected by concussions and traumatic brain injuries (TBI). Dr. Kelly's appointment to the Medical Board reflects his leadership in brain injury resear

    2/24/25 8:30:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

    SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith

    1/21/25 8:15:00 AM ET
    $MEDS
    $OGEN
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Oragenics Appoints William "Frank" Peacock MD as Chief Clinical Officer

    SARASOTA, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. William "Frank" Peacock as its Chief Clinical Officer, who will conduct its anticipated Phase II clinical trial for treating concussion in the Emergency Department ("ED"). Oragenics' lead drug candidate, ONP-002, is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (mTBI), commonly known as concussion, in the field and emergency departments. ONP-002 is a new chemical entity (NCE) designed to target the brain through deliver

    5/22/24 8:00:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 7:29:57 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 3:59:00 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Oragenics Inc.

    SC 13G - ORAGENICS INC (0001174940) (Subject)

    9/11/24 7:45:36 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care